UDP-003 atherosclerosis therapeutic program
phase 1drug program · high · Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a disease-modifying therapy for atherosclerotic disease by selectively removing toxic oxidized cholesterol, especially 7-ketocholesterol, from foam cells and arterial plaque biology.
Novel cyclodextrin-derived therapeutic candidate designed to bind and clear 7-ketocholesterol; evaluated in mouse and human monocyte/macrophage foam-cell models and advanced into first-in-human clinical testing.
Secured approval for a first-in-human clinical trial and reported first clinical data demonstrating excretion of oxidized cholesterol at the American Heart Association Vascular Discovery Scientific Sessions.
Preclinical evidence showed UDP-003 reversed foam-cell phenotype toward a macrophage-like phenotype, restored phagocytic function, and reduced reactive oxygen species and intracellular lipid droplet accumulation. Public-record title also reports clinical evidence of oxidized-cholesterol excretion, but supplied material does not provide detailed clinical values.
Modified cyclodextrin nomenclature system
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Standardize representation of modified cyclodextrin structures to support communication, data sharing, reproducibility, automation, and computational/AI-driven cyclodextrin optimization.
A nomenclature framework treating glucopyranose units as residue-like building blocks, with substitutions represented analogously to mutations to specify substitution type, number, position, cyclic permutation, chirality, and linked cyclodextrin oligomers.
Published a comprehensive nomenclature system for cyclodextrins.
The publication proposes an extensible naming system for structurally diverse modified cyclodextrins, addressing a stated barrier to automated molecular design and reproducible cyclodextrin research.
AI-driven cyclodextrin-sterol design research program
exploratoryresearch program · medium · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Enable predictive design of modified cyclodextrins for sterol binding, including cholesterol and 7-ketocholesterol, to support automated molecular design.
In silico potential-of-mean-force calculations from guided metadynamics simulations of modified beta-cyclodextrin inclusion complexes with cholesterol and 7-ketocholesterol; results intended to support AI algorithm training and automated design.
2024 publication reporting reproducible computational affinity methods and orientation/substitution effects for cyclodextrin-sterol complexes.
The study found distinct sterol orientation preferences, significant effects of cyclodextrin substitutions on binding, and a more efficient wide-face sampling approach with comparable binding energies to full-cavity sampling.
AI-driven modified cyclodextrin drug design platform
exploratoryplatform · medium · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Enable predictive design of modified cyclodextrins that bind sterol targets such as cholesterol and 7-ketocholesterol with improved affinity and specificity.
Computational platform using potential-of-mean-force calculations from guided metadynamics simulations to estimate affinity constants for modified beta-cyclodextrin inclusion complexes with cholesterol and 7-ketocholesterol.
2024 publication describing in silico affinity determination for modified cyclodextrin-sterol complexes.
The study reported reproducible simulations, sterol orientation preferences, substitution-dependent binding effects, and a faster wide-face sampling approach with comparable binding energies and lower statistical uncertainty.
Cyclodextrin dimer compositions program
undisclosedplatform · medium · Wed Aug 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Protect and develop cyclodextrin dimers, their compositions, and uses as part of Cyclarity/Underdog Pharmaceuticals' modified cyclodextrin technology base.
Patented cyclodextrin dimer chemical compositions; patent family includes filings by Underdog Pharmaceuticals and current assignee Cyclarity Therapeutics.
European patent application EP3906263A4 listed as pending, with publication date shown as 2022-08-31; related US patent family includes US11279774B2 in the public-record excerpt.
AI-driven cyclodextrin design platform
exploratoryplatform · medium
Enable predictive design and optimization of modified cyclodextrins that bind sterols such as cholesterol and 7-ketocholesterol with improved affinity and specificity.
Computational potential-of-mean-force calculations from guided metadynamics simulations to characterize 1:1 inclusion complexes between modified beta-cyclodextrins and sterol molecules, intended to support AI training and automated molecular design.
Published computational work establishing reproducible in silico affinity methods for cyclodextrin-sterol complexes.
The study found a consistent sterol orientation preference, showed that cyclodextrin substitutions materially affect binding, and reported that sampling only the wide face of the cyclodextrin cavity gave comparable binding energies to full-cavity sampling with less time and uncertainty.
Cyclodextrin cholesterol-clearance therapeutic platform
preclinicalplatform · high
Develop easy-to-use drugs to prevent age-related conditions such as atherosclerosis, heart attack, and stroke by clearing non-degradable cholesterol from arterial wall cells and targeting arterial plaque root causes.
Novel derivatives of cyclodextrins designed to bind and remove sterols, including cholesterol and 7-ketocholesterol, from cells and plaques.
Seed financing described as carrying development through candidate selection, lead testing, and initial regulatory filings for human clinical trials.
Site analysis states products are based on novel derivatives of well-known, safe compounds called cyclodextrins; filtered publications support cyclodextrin-sterol binding and 7KC-removal biology.
